SAN FRANCISCO – Jaguar Health, Inc. (NASDAQ:JAGX), a commercial stage pharmaceuticals company, announced today that it will implement a reverse stock split of its common stock at a ratio of 1-for-60, effective Thursday, May 23, 2024. The move is intended to maintain the company’s compliance with Nasdaq’s listing standards and to potentially make the stock more appealing to institutional investors.
The decision to proceed with the reverse stock split was made following a vote at a Special Meeting of Stockholders held in April 2024. A majority of voting power from common and Series J…